Protagonist Therapeutics, Inc. (PTGX)

The stock price of Protagonist Therapeutics, Inc. has been impacted by several key events over the past six months. The submission of a New Drug Application for rusfertide in polycythemia vera by Protagonist and its partner Takeda led to positive analyst sentiment and increased price targets. Several financial firms raised their price targets for PTGX, reflecting growing confidence in the company's regulatory trajectory and the potential of its pipeline. The company's CEO, CFO, and Chief Medical Officer engaged in significant insider selling of shares, contributing to the stock closing lower and a pullback in share price. PTGX experienced increased volatility and a pullback, with investors debating the stock's valuation. The company participated in several healthcare conferences, providing platforms for company updates that can influence investor sentiment. Positive data from the VERIFY trial for rusfertide was noted by analysts. PTGX shares reached a 52-week high of $96.54 and a 52-week low of $33.70, and as of February 4, 2026, the share price was $83.29, representing a 116.23% increase over the price on February 5, 2025.

Protagonist Therapeutics, Inc. does not currently have marketed products with established commercial demand seasonality. The company's value and prospects are primarily influenced by clinical trial results, regulatory milestones, and partnership developments, rather than seasonal consumer demand patterns. While historical stock returns can exhibit seasonal patterns, this is distinct from product demand seasonality.

Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel peptide-based new chemical entities to address unmet medical needs. The company specializes in both oral and injectable peptide drugs, targeting therapeutic areas such as hematology, blood disorders, and inflammatory and immunomodulatory diseases. Its major product pipeline includes Rusfertide (PTG-300), an injectable mimetic of hepcidin in Phase 3 clinical trials for polycythemia vera and other blood disorders; Icotrokinra, an orally delivered investigational drug in Phase 3 clinical trials for psoriasis, psoriatic arthritis, ulcerative colitis, and inflammatory bowel disease; PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist that has completed Phase 2 clinical trials in patients with moderate to severe ulcerative colitis; PN-881, an IL-17 oral peptide antagonist in pre-clinical stage; and other preclinical programs including an oral metabolic/obesity peptide program and an oral hepcidin mimetic/ferroportin blocker.

Protagonist Therapeutics, Inc. is headquartered in Newark, California, United States. Its primary operations are focused on research, development, and clinical trials, which are typically managed from its headquarters. Specific details on a broader geographic footprint for commercial sales or extensive international operations are not publicly detailed, as its lead products are still in advanced clinical development or regulatory review.

Protagonist Therapeutics generally holds a positive reputation within the financial and biotechnology communities, largely driven by its promising clinical pipeline and regulatory progress. The company has received a consensus rating of "Moderate Buy" from analysts, with a strong majority of buy ratings. The successful submission of the NDA for rusfertide and advancing partnerships for its other drug candidates contribute positively to its standing. Recent insider selling activity could be viewed with caution by some investors, it has not significantly altered the overall positive analyst sentiment.

The ownership structure of Protagonist Therapeutics is a mix of institutional, retail, and individual investors. Approximately 39.97% of the company's stock is owned by Institutional Investors, 1.47% by Insiders, and 58.56% by Public Companies and Individual Investors. However, another source indicates that 98.63% of the stock is held by institutions and 4.90% by insiders. Major institutional owners include BlackRock, Inc., Farallon Capital Management Llc, Rtw Investments, Lp, Vanguard Group Inc, iShares Core S&P Small-Cap ETF (IJR), State Street Corp, UBS Group AG, Bvf Inc/il, Johnson & Johnson, and Vanguard Total Stock Market Index Fund Investor Shares (VTSMX).